Src-mediated regulation of homotypic cell adhesion: Implications for cancer progression and opportunities for therapeutic intervention

Cancer Treatment Reviews

Volumn 37, Issue 3, 2011, Pages 234-241

  Wadhawan, Anshu ^a   Smith, Chris ^a   Nicholson, Robert I ^b   Barrett Lee, Peter ^a   Hiscox, Stephen ^b  

^a VELINDRE CANCER CENTRE   (United Kingdom)

^b CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

catenin; Adherens junction; Cancer; Clinical trials; E cadherin; Invasion; Src; Src inhibitors

Indexed keywords

4 AMINO 7 TERT BUTYL 5 (4 CHLOROPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; ALPHA CATENIN; BETA CATENIN; BOSUTINIB; CADHERIN; CLATHRIN; DASATINIB; GELATINASE B; MESSENGER RNA; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; RAS PROTEIN; SARACATINIB; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; XL 999;

ACUTE LYMPHOCYTIC LEUKEMIA; BONE METASTASIS; BREAST CANCER; BREAST METASTASIS; CANCER CELL; CANCER GROWTH; CELL ADHESION; CELL INVASION; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CELL SURVIVAL; CHRONIC MYELOID LEUKEMIA; COLORECTAL CANCER; EWING SARCOMA; HEAD AND NECK CANCER; HUMAN; LIVER CANCER; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; OVARY CANCER; PANCREAS CANCER; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVIEW; SOLID TUMOR; STOMACH CANCER;

ANIMALS; CELL ADHESION; CELL MOVEMENT; DISEASE PROGRESSION; HUMANS; NEOPLASM INVASIVENESS; NEOPLASMS; SRC-FAMILY KINASES;

EID: 79952003043     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2010.08.003     Document Type: Review

References (106)

1. Martin G.S. The road to Src. Oncogene 2004, 23(48):7910-7917.
2. Yeatman T.J. A renaissance for SRC. Nat Rev Cancer 2004, 4(6):470-480.
3. Irby R.B., Yeatman T.J. Role of Src expression and activation in human cancer. Oncogene 2000, 19(49):5636-5642.
4. Rosen N., Bolen J.B., Schwartz A.M., Cohen P., DeSeau V., Israel M.A. Analysis of pp60c-src protein kinase activity in human tumor cell lines and tissues. J Biol Chem 1986, 261(29):13754-13759.
5. Summy J.M., Gallick G.E. Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev 2003, 22(4):337-358.
6. Verbeek B.S., Vroom T.M., Adriaansen-Slot S.S., et al. C-Src protein expression is increased in human breast cancer. An immunohistochemical and biochemical analysis. J Pathol 1996, 180(4):383-388.
7. Wilson G.R., Cramer A., Welman A., et al. Activated c-SRC in ductal carcinoma in situ correlates with high tumour grade, high proliferation and HER2 positivity. Br J Cancer 2006, 95(10):1410-1414.
8. Aligayer H., Boyd D.D., Heiss M.M., Abdalla E.K., Curley S.A., Gallick G.E. Activation of Src kinase in primary colorectal carcinoma: an indicator of poor clinical prognosis. Cancer 2002, 94(2):344-351.
9. Biscardi J.S., Ishizawar R.C., Silva C.M., Parsons S.J. Tyrosine kinase signalling in breast cancer: epidermal growth factor receptor and c-Src interactions in breast cancer. Breast Cancer Res 2000, 2(3):203-210.
10. Irby R.B., Mao W., Coppola D., et al. Activating SRC mutation in a subset of advanced human colon cancers. Nat Genet 1999, 21(2):187-190.
11. Sugimura M., Kobayashi K., Sagae S., et al. Mutation of the SRC gene in endometrial carcinoma. Jpn J Cancer Res 2000, 91(4):395-398.
12. Wang N.M.Y.K., Tsai C.H., Chen S.J., Chang J.G. No evidence of correlation between mutation at codon 531 of src and the risk of colon cancer in Chinese. Cancer Lett 2000, 150(2):201-204.
13. Laghi L., Bianchi P., Orbetegli O., Gennari L., Roncalli M., Malesci A. Lack of mutation at codon 531 of SRC in advanced colorectal cancers from Italian patients. Br J Cancer 2001, 84(2):196-198.
14. Huveneers S., van den Bout I., Sonneveld P., Sancho A., Sonnenberg A., Danen E.H. Integrin alpha v beta 3 controls activity and oncogenic potential of primed c-Src. Cancer Res 2007, 67(6):2693-2700.
15. Galliher A.J., Schiemann W.P. Beta3 integrin and Src facilitate transforming growth factor-beta mediated induction of epithelial-mesenchymal transition in mammary epithelial cells. Breast Cancer Res 2006, 8(4):R42.
16. Silva C.M. Role of STATs as downstream signal transducers in Src family kinase-mediated tumorigenesis. Oncogene 2004, 23(48):8017-8023.
17. Brunton V.G., Avizienyte E., Fincham V.J., et al. Identification of Src-specific phosphorylation site on focal adhesion kinase: dissection of the role of Src SH2 and catalytic functions and their consequences for tumor cell behavior. Cancer Res 2005, 65(4):1335-1342.
18. Cowell L.N., Graham J.D., Bouton A.H., Clarke C.L., O'Neill G.M. Tamoxifen treatment promotes phosphorylation of the adhesion molecules, p130Cas/BCAR1, FAK and Src, via an adhesion-dependent pathway. Oncogene 2006, 25(58):7597-7607.
19. McGarrigle D., Huang X.Y. GPCRs signaling directly through Src-family kinases. Sci STKE 2007, 2007(392):pe35.
20. Frame M.C. Src in cancer: deregulation and consequences for cell behaviour. Biochim Biophys Acta 2002, 1602(2):114-130.
21. Wang X., Zhang J., Fan M., et al. The expression of E-cadherin at the invasive tumor front of oral squamous cell carcinoma: immunohistochemical and RT-PCR analysis with clinicopathological correlation. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2009, 107(4):547-554.
22. Ohashi M., Kusumi T., Sato F., et al. Expression of syndecan-1 and E-cadherin is inversely correlated with poor patient's prognosis and recurrent status of extrahepatic bile duct carcinoma. Biomed Res 2009, 30(2):79-86.
23. Bansal N., Yendluri V., Wenham R.M. The molecular biology of endometrial cancers and the implications for pathogenesis, classification, and targeted therapies. Cancer Control 2009, 16(1):8-13.
24. Boggon T.J., Murray J., Chappuis-Flament S., Wong E., Gumbiner B.M., Shapiro L. C-cadherin ectodomain structure and implications for cell adhesion mechanisms. Science 2002, 296(5571):1308-1313.
25. Haussinger D., Ahrens T., Aberle T., Engel J., Stetefeld J., Grzesiek S. Proteolytic E-cadherin activation followed by solution NMR and X-ray crystallography. EMBO J 2004, 23(8):1699-1708.
26. Leckband D., Sivasankar S. Mechanism of homophilic cadherin adhesion. Curr Opin Cell Biol 2000, 12(5):587-592.
27. Takeichi M., Nakagawa S., Aono S., Usui T., Uemura T. Patterning of cell assemblies regulated by adhesion receptors of the cadherin superfamily. Philos Trans R Soc London B Biol Sci 2000, 355(1399):885-890.
28. Takeichi M. Cadherins in cancer: implications for invasion and metastasis. Curr Opin Cell Biol 1993, 5(5):806-811.
29. Onder T.T., Gupta P.B., Mani S.A., Yang J., Lander E.S., Weinberg R.A. Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways. Cancer Res 2008, 68(10):3645-3654.
30. Howard E.W., Camm K.D., Wong Y.C., Wang X.H. E-cadherin upregulation as a therapeutic goal in cancer treatment. Mini Rev Med Chem 2008, 8(5):496-518.
31. Hudson L.G., Zeineldin R., Stack M.S. Phenotypic plasticity of neoplastic ovarian epithelium: unique cadherin profiles in tumor progression. Clin Exp Metastasis 2008, 25(6):643-655.
32. Behrens J., Behrens J., Frixen U., Schipper J., Weidner M., Birchmeier W. The role of cell adhesion molecules in cancer invasion and metastasis cell adhesion in invasion and metastasis. Breast Cancer Res Treat 1993, 24(3):175-184.
33. Vleminckx K., Vakaet L., Mareel M., Fiers W., van Roy F. Genetic manipulation of E-cadherin expression by epithelial tumor cells reveals an invasion suppressor role. Cell 1991, 66(1):107-119.
34. Benjamin J.M., Nelson W.J. Bench to bedside and back again: molecular mechanisms of alpha-catenin function and roles in tumorigenesis. Semin Cancer Biol 2008, 18(1):53-64.
35. Brembeck F.H., Rosario M., Birchmeier W. Balancing cell adhesion and Wnt signaling, the key role of beta-catenin. Curr Opin Genet Dev 2006, 16(1):51-59.
36. Chung Y., Lam A.K., Luk J.M., et al. Altered E-cadherin expression and p120 catenin localization in esophageal squamous cell carcinoma. Ann Surg Oncol 2007, 14(11):3260-3267.
37. Kim M.J., Jang S.J., Yu E. Loss of E-cadherin and cytoplasmic-nuclear expression of beta-catenin are the most useful immunoprofiles in the diagnosis of solid-pseudopapillary neoplasm of the pancreas. Hum Pathol 2008, 39(2):251-258.
38. Chen S., Liu J., Li G., et al. Altered distribution of beta-catenin and prognostic roles in colorectal carcinogenesis. Scand J Gastroenterol 2008, 43(4):456-464.
39. Hsu P.K., Li A.F., Wang Y.C., et al. Reduced membranous beta-catenin protein expression is associated with metastasis and poor prognosis in squamous cell carcinoma of the esophagus. J Thorac Cardiovasc Surg 2008, 135(5):1029-1035.
40. Kashibuchi K., Tomita K., Schalken J.A., Kume H., Takeuchi T., Kitamura T. The prognostic value of E-cadherin, alpha-, beta- and gamma-catenin in bladder cancer patients who underwent radical cystectomy. Int J Urol 2007, 14(9):789-794.
41. van Oort I.M., Tomita K., van Bokhoven A., et al. The prognostic value of E-cadherin and the cadherin-associated molecules alpha-, beta-, gamma-catenin and p120ctn in prostate cancer specific survival: a long-term follow-up study. Prostate 2007, 67(13):1432-1438.
42. Shimazui T., Schalken J.A., Giroldi L.A., et al. Prognostic value of cadherin-associated molecules (alpha-, beta-, and gamma-catenins and p120(cas)) in bladder tumors. Cancer Res 1996, 56(18):4154-4158.
43. Shimazui T., Bringuier P.P., van Berkel H., et al. Decreased expression of alpha-catenin is associated with poor prognosis of patients with localized renal cell carcinoma. Int J Cancer 1997, 74(5):523-528.
44. Kreizenbeck G.M., Berger A.J., Subtil A., Rimm D.L., Gould Rothberg B.E. Prognostic significance of cadherin-based adhesion molecules in cutaneous malignant melanoma. Cancer Epidemiol Biomarkers Prev 2008, 17(4):949-958.
45. Salahshor S., Naidoo R., Serra S., et al. Frequent accumulation of nuclear E-cadherin and alterations in the Wnt signaling pathway in esophageal squamous cell carcinomas. Mod Pathol 2008, 21(3):271-281.
46. Palacios F., Tushir J.S., Fujita Y., D'Souza-Schorey C. Lysosomal targeting of E-cadherin: a unique mechanism for the down-regulation of cell-cell adhesion during epithelial to mesenchymal transitions. Mol Cell Biol 2005, 25(1):389-402.
47. Brown M.T., Andrade J., Radhakrishna H., Donaldson J.G., Cooper J.A., Randazzo P.A. ASAP1, a phospholipid-dependent arf GTPase-activating protein that associates with and is phosphorylated by Src. Mol Cell Biol 1998, 18(12):7038-7051.
48. Kon S., Tanabe K., Watanabe T., Sabe H., Satake M. Clathrin dependent endocytosis of E-cadherin is regulated by the Arf6GAP isoform SMAP1. Exp Cell Res 2008, 314(7):1415-1428.
49. Palacios F., D'Souza-Schorey C. Modulation of Rac1 and ARF6 activation during epithelial cell scattering. J Biol Chem 2003, 278(19):17395-17400.
50. Tsukamoto T., Nigam S.K. Cell-cell dissociation upon epithelial cell scattering requires a step mediated by the proteasome. J Biol Chem 1999, 274(35):24579-24584.
51. Shen Y., Hirsch D.S., Sasiela C.A., Wu W.J. Cdc42 regulates E-cadherin ubiquitination and degradation through an epidermal growth factor receptor to Src-mediated pathway. J Biol Chem 2008, 283(8):5127-5137.
52. Fujita Y., Krause G., Scheffner M., et al. Hakai, a c-Cbl-like protein, ubiquitinates and induces endocytosis of the E-cadherin complex. Nat Cell Biol 2002, 4(3):222-231.
53. Symowicz J., Adley B.P., Gleason K.J., et al. Engagement of collagen-binding integrins promotes matrix metalloproteinase-9-dependent E-cadherin ectodomain shedding in ovarian carcinoma cells. Cancer Res 2007, 67(5):2030-2039.
54. De Wever O., Derycke L., Hendrix A., et al. Soluble cadherins as cancer biomarkers. Clin Exp Metastasis 2007, 24(8):685-697.
55. Ulianich L., Garbi C., Treglia A.S., et al. ER stress is associated with dedifferentiation and an epithelial-to-mesenchymal transition-like phenotype in PC Cl3 thyroid cells. J Cell Sci 2008, 121(Pt 4):477-486.
56. Wei J.C., Xu G., Wu M.F., et al. Overexpression of vimentin contributes to prostate cancer invasion and metastasis via src regulation. Anticancer Res 2008, 28(1A):327-334.
57. Cicchini C., Laudadio I., Citarella F., et al. TGFbeta-induced EMT requires focal adhesion kinase (FAK) signaling. Exp Cell Res 2008, 314(1):143-152.
58. Yap A.S., Daniel J.M. Taking stock: the many surprising lives of p120-catenins. Biochim Biophys Acta (BBA) - Mol Cell Res 2007, 1773(1):1.
59. van Hengel J., van Roy F. Diverse functions of p120ctn in tumors. Biochim Biophys Acta 2007, 1773(1):78-88.
60. Silva Neto B., Smith G.L., Mandeville J.A., et al. Prognostic significance of altered p120 ctn expression in bladder cancer. BJU Int 2008, 101(6):746-752.
61. Liu Y., Xu H.T., Dai S.D., Wei Q., Yuan X.M., Wang E.H. Reduction of p120(ctn) isoforms 1 and 3 is significantly associated with metastatic progression of human lung cancer. APMIS 2007, 115(7):848-856.
62. Ozawa M., Ohkubo T. Tyrosine phosphorylation of p120(ctn) in v-Src transfected L cells depends on its association with E-cadherin and reduces adhesion activity. J Cell Sci 2001, 114(3):503-512.
63. Piedra J., Miravet S., Castano J., et al. p120 catenin-associated Fer and Fyn tyrosine kinases regulate beta-catenin Tyr-142 phosphorylation and beta-catenin-alpha-catenin interaction. Mol Cell Biol 2003, 23(7):2287-2297.
64. Mariner D.J., Anastasiadis P., Keilhack H., Bohmer F.D., Wang J., Reynolds A.B. Identification of Src phosphorylation sites in the catenin p120(ctn). J Biol Chem 2001, 276(30):28006-28013.
65. Alema S., Salvatore A.M. P120 catenin and phosphorylation: mechanisms and traits of an unresolved issue. Biochim Biophys Acta 2007, 1773(1):47-58.
66. Lilien J., Balsamo J. The regulation of cadherin-mediated adhesion by tyrosine phosphorylation/dephosphorylation of beta-catenin. Curr Opin Cell Biol 2005, 17(5):459-465.
67. Aberle H., Schwartz H., Hoschuetzky H., Kemler R. Single amino acid substitutions in proteins of the armadillo gene family abolish their binding to alpha-catenin. J Biol Chem 1996, 271(3):1520-1526.
68. Ozawa M., Kemler R. Altered cell adhesion activity by pervanadate due to the dissociation of alpha-catenin from the E-cadherin.catenin complex. J Biol Chem 1998, 273(11):6166-6170.
69. Roura S., Miravet S., Piedra J., Garcia de Herreros A., Dunach M. Regulation of E-cadherin/catenin association by tyrosine phosphorylation. J Biol Chem 1999, 274(51):36734-36740.
70. Rhee J., Mahfooz N.S., Arregui C., Lilien J., Balsamo J., VanBerkum M.F. Activation of the repulsive receptor Roundabout inhibits N-cadherin-mediated cell adhesion. Nat Cell Biol 2002, 4(10):798-805.
71. Burks J., Agazie Y.M. Modulation of alpha-catenin Tyr phosphorylation by SHP2 positively effects cell transformation induced by the constitutively active FGFR3. Oncogene 2006, 25(54):7166-7179.
72. Carothers A.M., Javid S.H., Moran A.E., Hunt D.H., Redston M., Bertagnolli M.M. Deficient E-cadherin adhesion in C57BL/6J-Min/+mice is associated with increased tyrosine kinase activity and RhoA-dependent actomyosin contractility. Exp Cell Res 2006, 312(4):387-400.
73. Behrens J., Vakaet L., Friis R., et al. Loss of epithelial differentiation and gain of invasiveness correlates with tyrosine phosphorylation of the E-cadherin/beta-catenin complex in cells transformed with a temperature-sensitive v-SRC gene. J Cell Biol 1993, 120(3):757-766.
74. Lawler K., O'Sullivan G., Long A., Kenny D. Shear stress induces internalization of E-cadherin and invasiveness in metastatic oesophageal cancer cells by a Src-dependent pathway. Cancer Sci 2009.
75. Coluccia A.M., Benati D., Dekhil H., De Filippo A., Lan C., Gambacorti-Passerini C. SKI-606 decreases growth and motility of colorectal cancer cells by preventing pp60(c-Src)-dependent tyrosine phosphorylation of beta-catenin and its nuclear signaling. Cancer Res 2006, 66(4):2279-2286.
76. Miotti S., Tomassetti A., Facetti I., Sanna E., Berno V., Canevari S. Simultaneous expression of caveolin-1 and E-cadherin in ovarian carcinoma cells stabilizes adherens junctions through inhibition of src-related kinases. Am J Pathol 2005, 167(5):1411-1427.
77. Ali N., Yoshizumi M., Yano S., et al. The novel Src kinase inhibitor M475271 inhibits VEGF-induced vascular endothelial-cadherin and beta-catenin phosphorylation but increases their association. J Pharmacol Sci 2006, 102(1):112-120.
78. Hiscox S., Morgan L., Green T., Nicholson R.I. Src as a therapeutic target in anti-hormone/anti-growth factor-resistant breast cancer. Endocr Relat Cancer 2006, 13(Suppl. 1):S53-S59.
79. Zhao Y., Planas-Silva M.D. Mislocalization of cell-cell adhesion complexes in tamoxifen-resistant breast cancer cells with elevated c-Src tyrosine kinase activity. Cancer Lett 2009, 275(2):204-212.
80. Wadhawan A B.-L.P., Smith C., Nicholson R.I., Hiscox S. Src-dependant changes in beta catenin activity promote a migratory phenotype in endocrine -resistant breast cancer cells. Cancer Res (Suppl) 2009, 69(24).
81. Borley A.C., Hiscox S., Gee J., et al. Anti-oestrogens but not oestrogen deprivation promote cellular invasion in intercellular adhesion-deficient breast cancer cells. Breast Cancer Res 2008, 10(6):R103.
82. Guan H., Zhou Z., Gallick G.E., et al. Targeting Lyn inhibits tumor growth and metastasis in Ewing's sarcoma. Mol Cancer Ther 2008, 7(7):1807-1816.
83. Avizienyte E., Frame M.C. Src and FAK signalling controls adhesion fate and the epithelial-to-mesenchymal transition. Curr Opin Cell Biol 2005, 17(5):542-547.
84. Tan M., Li P., Sun M., Yin G., Yu D. Upregulation and activation of PKC alpha by ErbB2 through Src promotes breast cancer cell invasion that can be blocked by combined treatment with PKC alpha and Src inhibitors. Oncogene 2006, 25(23):3286-3295.
85. Jallal H., Valentino M.L., Chen G., Boschelli F., Ali S., Rabbani S.A. A Src/Abl kinase inhibitor, SKI-606, blocks breast cancer invasion, growth, and metastasis in vitro and in vivo. Cancer Res 2007, 67(4):1580-1588.
86. Trevino J.G., Summy J.M., Lesslie D.P., et al. Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model. Am J Pathol 2006, 168(3):962-972.
87. Benistant C., Chapuis H., Mottet N., et al. Deregulation of the cytoplasmic tyrosine kinase cSrc in the absence of a truncating mutation at codon 531 in human bladder carcinoma. Biochem Biophys Res Commun 2000, 273(2):425-430.
88. Chen J.Y., Hung C.C., Huang K.L., et al. Src family kinases mediate betel quid-induced oral cancer cell motility and could be a biomarker for early invasion in oral squamous cell carcinoma. Neoplasia 2008, 10(12):1393-1401.
89. Guarino M., Rubino B., Ballabio G. The role of epithelial-mesenchymal transition in cancer pathology. Pathology 2007, 39(3):305-318.
90. Fendrich V., Waldmann J., Feldmann G., et al. Unique expression pattern of the EMT markers Snail, Twist and E-cadherin in benign and malignant parathyroid neoplasia. Eur J Endocrinol 2009, 160(4):695-703.
91. Usami Y., Satake S., Nakayama F., et al. Snail-associated epithelial-mesenchymal transition promotes oesophageal squamous cell carcinoma motility and progression. J Pathol 2008, 215(3):330-339.
92. Bankfalvi A., Krassort M., Buchwalow I.B., Vegh A., Felszeghy E., Piffko J. Gains and losses of adhesion molecules (CD44, E-cadherin, and beta-catenin) during oral carcinogenesis and tumour progression. J Pathol 2002, 198(3):343-351.
93. Brabletz T., Jung A., Reu S., et al. Variable beta-catenin expression in colorectal cancers indicates tumor progression driven by the tumor environment. Proc Natl Acad Sci USA 2001, 98(18):10356-10361.
94. Hiscox S., Jordan N.J., Morgan L., Green T.P., Nicholson R.I. Src kinase promotes adhesion-independent activation of FAK and enhances cellular migration in tamoxifen-resistant breast cancer cells. Clin Exp Metastasis 2007, 24(3):157-167.
95. Hiscox S., Morgan L., Green T.P., Barrow D., Gee J., Nicholson R.I. Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells. Breast Cancer Res Treat 2006, 97(3):263-274.
96. Rucci N., Recchia I., Angelucci A., et al. Inhibition of protein kinase c-Src reduces the incidence of breast cancer metastases and increases survival in mice: implications for therapy. J Pharmacol Exp Ther 2006, 318(1):161-172.
97. Evans T Rea A dose ecsalation study of SRC and multikinase inhibitor BMS-354825 in patients with GIST and other solid tumors (abstract). J Clin Oncol 2005, 23(Suppl):3034.
98. Messersmith WA KS, Hewes BA, et al.. Bosutinib(SKI-606), a dual src/Abl tyrosine kinase inhibitor: preliminary results from a phase I study in patients with advanced malignant solid tumors. J Clin Oncol ASCO Ann Meet Proc Part 1 2007;25.
99. Jones R.J., Young O., Renshaw L., et al. Src inhibitors in early breast cancer: a methodology, feasibility and variability study. Breast Cancer Res Treat 2009, 114(2):211-221.
100. Shor A.C., Keschman E.A., Lee F.Y., et al. Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on SRC kinase for survival. Cancer Res 2007, 67(6):2800-2808.
101. Finn R.S., Dering J., Ginther C., et al. Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/" triple-negative" breast cancer cell lines growing in vitro. Breast Cancer Res Treat 2007, 105(3):319-326.
102. Huang F., Reeves K., Han X., et al. Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection. Cancer Res 2007, 67(5):2226-2238.
103. Tabernero J CA HK, et al. Phase I study of AZD0530, an oral potent inhibitor of src kinase: first demonstration of inhibition of src activity in human cancers. J Clin Oncol 2007;25:3250.
104. Perou C.M.S.T., Eisen M.B., et al. Molecular portraits of human breast tumors. Nature 2000, 406:747-752.
105. Sortiriou C NS MLa. Breast cancer classification and prognosis based on gene expression profiles from a population based study. In: Proceedings of the national academy of sciences of the United States of America, vol. 100. 2003. p. 10393-8.
106. Bild AHea. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 2006;(439):353-7.